Herpes simplex virus thymidine kinase (HSVTK) with the guanosine analog ganciclovir (GCV) is currently the most widely used suicide gene/prodrug system for gene therapy of cancer. Despite the broad application of the HSVTK/GCV approach, phosphorylation of GCV to its active state is inefficient such that high, myelosuppressive doses of GCV are needed to observe an antitumor effect. One strategy used to overcome the poor substrate specificity of HSVTK towards GCV (K m ¼ 45 mM) has been to create novel forms of TK with altered substrate preferences. Such mutant TKs have shown benefit and are currently in clinical use. We describe here a second strategy to increase the amount of intracellular triphosphorylated GCV by involving the second enzyme in the GCV activation pathway, guanylate kinase (GMK). As a means to overcome the bottleneck of prodrug activation from the monophosphate to the diphosphate, we sought to combine both the critical HSVTK and GMK activities together. In this report we describe the construction of a fusion or chimeric protein of HSVTK and guanylate kinase, show data that demonstrate it confers a B175-fold decrease in IC 50 compared to HSVTK alone in response to ganciclovir treatment in stably transfected C6 glioma cells and finally, we present biochemical evidence of a kinetic basis for this improved cell killing.
Herpes simplex virus thymidine kinase (HSVTK) with the guanosine analog ganciclovir (GCV) is currently the most widely used suicide gene/prodrug system for gene therapy of cancer. Despite the broad application of the HSVTK/GCV approach, phosphorylation of GCV to its active state is inefficient such that high, myelosuppressive doses of GCV are needed to observe an antitumor effect. One strategy used to overcome the poor substrate specificity of HSVTK towards GCV (K m ¼ 45 mM) has been to create novel forms of TK with altered substrate preferences. Such mutant TKs have shown benefit and are currently in clinical use. We describe here a second strategy to increase the amount of intracellular triphosphorylated GCV by involving the second enzyme in the GCV activation pathway, guanylate kinase (GMK). As a means to overcome the bottleneck of prodrug activation from the monophosphate to the diphosphate, we sought to combine both the critical HSVTK and GMK activities together. In this report we describe the construction of a fusion or chimeric protein of HSVTK and guanylate kinase, show data that demonstrate it confers a B175-fold decrease in IC 50 compared to HSVTK alone in response to ganciclovir treatment in stably transfected C6 glioma cells and finally, we present biochemical evidence of a kinetic basis for this improved cell killing. Gene Therapy (2006) Herpes simplex virus thymidine kinase (HSVTK) is widely used as a suicide gene in combination with ganciclovir (GCV) for the treatment of a variety of cancers. To date, over 70 clinical gene therapy trials using HSVTK have been approved. 1 Moolten first described the potential application of HSVTK for cancer treatment based on its ability to phosphorylate the antiviral drug GCV. 2 Following delivery of the gene encoding HSVTK to cancer cells, the prodrug is administered. Because HSVTK, but not the endogenous thymidine kinase (TK), is able to phosphorylate GCV, cytotoxicity is limited to the site of transfection. Once monophosphorylated, GCV is further phosphorylated to the triphosphate by the endogenously expressed enzymes, guanylate kinase (GMK) and nucleoside diphophokinases, respectively. In the triphosphorylated state, GCV competes with deoxyguanosine triphosphate (dGTP) for incorporation into the nascent DNA strand by DNA polymerase and once incorporated prevents chain elongation that subsequently results in apoptosis. 3, 4 A major factor in tumor ablation using the HSVTK/ GCV approach involves the transfer of antimetabolites to neighboring untransfected cells through gap junctions or via apoptotic vesicles. 5, 6 Implicit in the bystander effect is that sufficient phosphorylated GCV be transferred to neighboring cells to elicit cell killing. As such, to achieve complete ablation, myelosuppressive doses of GCV are required. Several approaches have been reported with varying success to overcome high-dose treatments including the use of multiple gene copies to yield high expression, 7 modulation of nucleoside-metabolizing pathways using drugs, 8 application of dual suicide gene/dual prodrug approaches 9 and the use of mutant suicide genes with improved kinetic parameters towards the prodrug. 10, 11 In this report, we describe a novel approach taking advantage of the GCV phosphorylation pathway to overcome the limitations in the intracellular conversion of GCV-monophosphate generated by HSVTK to the toxic GCV-triphosphate. There is evidence that once the prodrug monophosphate is formed, a bottleneck occurs, leading to accumulation of the ineffective intermediate product. [12] [13] [14] Responsible for the second phosphorylation step of GCV and its close relative acyclovir (ACV), GMK is an essential enzyme whose expression level and specificity is likely a key determinant in the overall efficacy of the HSVTK/GCV approach. 15, 16 While thymidine kinase from herpes simplex virus type I displays broad substrate specificity and can phosphorylate pyrimidines and both pyrimidine and purine analogs including thymidine, deoxycytidine, azidothymidine, acyclovir and GCV, GMK has a restricted substrate specificity and phosphorylates only the mono-phosphorylated forms of guanosine (GMP), deoxyguanosine (dGMP) and guanosine analogs such as GCV and ACV (GCV-MP, ACV-MP). [15] [16] [17] [18] From an enzyme kinetic perspective, the high K m of GMK for GCV-MP (K m ¼ 42-54 mM) compared to the K m for GMP (B25 mM) supports the notion that low endogenous GMK activity may limit production of the pharmacologically active form of GCV. 15, 19 As a means to overcome the bottleneck of prodrug activation at the mono-to diphosphate step, we combined both the critical HSVTK and GMK activities together in a single fusion or chimeric protein and assessed the ability of pathway engineering to reduce to the level of GCV required for effective cell killing.
To construct the gmk/HSVTK fusion gene, the mouse gmk (mgmk) gene was isolated from pET23d:mgmk as an BglII/MscI fragment and ligated to BglII/MluI(bluntended)-digested pET23d:HSVTK. 10, 19 The resulting plasmid, designated pET23d:mgmk/TK, was sequenced to confirm in-frame fusion of the two genes. As a result of the cloning sites used, the first nine amino acids of HSVTK and the last two amino acids of MGMK were deleted.
To rapidly assess the functionality of the fusion construct with respect to both HSVTK and GMK activities, genetic complementation for both activities was independently evaluated. We previously described the establishment of an Escherichia coli strain (TS202A(DE3)) that is deficient in TK activity (tdk À ) and is conditionally gmk deficient. 20 Briefly, the mouse gmk gene was integrated into the arabinose operon of E. coli KY895 (ilv À tdk À ) to provide induction of GMK protein expression in the presence of arabinose. The bacterial gmk was disrupted by insertion of a kanamycinresistance gene into the bacterial gmk locus by recombination. Because GMK is an essential enzyme, E. coli TS202A(DE3) requires the presence of arabinose. In the absence of arabinose, no gmk is expressed and the cells are nonviable. TS202A(DE3) cells were transformed with pET23d, pET23d:HSVTK, pET23d:mgmk or the fusion construct, pET23d:mgmk/TK. Cultures were grown in M9 minimal medium in the presence of arabinose to allow the expression of endogenous mouse GMK at 371C overnight before streaking onto TK selection plates 10 containing arabinose, M9 plates plus arabinose or M9 plates without arabinose. 20 As anticipated, cells harboring pET23d and pET23d:mgmk were not able to complement the TK deficiency of TS202A(DE3), whereas cells harboring pET23d:HSVTK and pET23d:mgmk/TK were viable (Figure 1a) . Similarly, only pET23d:mgmkand pET23d:mgmk/TK-transformed TS202A(DE3) were viable on M9 plates in the absence of arabinose ( Figure  1b) . These results indicate that the fusion protein is expressed and maintains both TK and GMK activities. All cultures grew on the control M9 with arabinose plates.
With confirmation of both TK and GMK activities in the fusion protein, we next sought to evaluate the ability of the fusion gene to sensitize cancer cells to GCV. Toward this end, the HSVTK, mgmk and mgmk/TK genes were subcloned into the pREP8D7 vector as described in Kokoris et al. 21 Rat C6 glioma cells were transfected using electroporation with the vector control (pREP8D7:dual-GFP) and vectors containing HSVTK, mgmk or mgmk/ TK. Insertion of HSVTK, mgmk or the fusion gene into this vector allows expression from an RSV LTR promoter. Following initial selection on histidinol, GFP expressed from a constituitive metallothionein promoter enabled cell sorting based on GFP expression to enrich transfectant pools. Immunoblots using polyclonal serum raised against HSVTK or MGMK were performed on transfectant lysates and show the presence of HSVTK at around 45 kDa when the anti-TK serum is used, and MGMK at around 23 kDa when anti-MGMK serum is used (data not shown). These results are in accord with the proteins' respective predicted molecular masses. The fusion protein cross-reacted with both anti-sera at the predicted molecular mass of approximately 68 kDa. Relatively equivalent protein levels were also observed.
To determine the cytotoxicity of GCV, transfected pools were plated in eight replicates and treated with a wide range of GCV concentrations (0-100 mM). Cell survival was assessed after 7 days using the redox indicator Alamar Blue and is expressed as a percentage of control wells that did not receive GCV (0 mM). Figure 2 shows a representative GCV-sensitivity curve of the rat C6 glioma cells transfected with pREP8D7:dual-GFP (vector alone), pREP8D7:TK-GFP, pREP8D7:mgmk-GFP and pREP8D7:mgmk/TK-GFP. Vector control and mgmktransfected cells were unaffected by GCV treatment. Cells expressing the fusion protein MGMK/TK were sensitive to GCV concentrations two orders of magnitude lower than those cells expressing HSVTK (IC 50 ¼ 70 and 
À 276 kan R ara À ) was used for genetic complementation of GMK and TK activities as well as for protein expression. 20 For culturing purposes, cells were grown on 2 Â YT (16 g tryptone, 10 g yeast extract, 5 g NaCl per liter) containing 0.2% L-arabinose and 50 mg/ml kanamycin. Carbenicillin was added to 50 mg/ml to media for growth of vector-transformed cells. For complementation of the tdk deficiency, TK selection medium plates 10 supplemented with arabinose and kanamycin were used. For gmk complementation, M9 minimal medium plates containing kanamycin with or without arabinose were used. 20 Guanylate kinase/thymidine kinase fusion protein CL Willmon et al 0.4 mM, respectively). As such, the approximately 175-fold lower IC 50 value observed with the fusion construct may be highly relevant in clinical settings where high doses of GCV are not well tolerated by patients. Erbs et al. 22 report similar findings when cells were transduced with an adenoviral vector expressing a yeast cytosine deaminase:uridine phosphoryltransferase fusion protein compared to cytosine deaminase.
Although earlier experiments co-expressing HSVTK and MGMK as separate proteins did not demonstrate more than twofold alteration in GCV sensitivity (data not shown and Akyü rek et al. 23 ), the substantial improvement observed with the fusion protein prompted us to investigate whether functional changes towards GCV are a result of fusing the two proteins together. Towards this end, MGMK, HSVTK and the fusion protein were purified to 495% homogeneity using affinity chromatography and their respective kinetic parameters determined (Table 1) . For all substrates examined, the k cat is 1.8-2.9-fold higher (Po0.002) with the fusion enzyme versus the respective single enzymes. This indicates that the fusion enzyme has an overall improved turnover rate for all substrates. Interestingly, whereas MGMK/TK K m values for the normal substrates (GMP and thymidine) are 2.4-3.8-fold higher (Po0.008 for both substrates), respectively, the K m for GCV is over threefold lower (P ¼ 0.006) and is suggestive of an increased relative preference for binding GCV. Perhaps most revealing is that the k cat /K m value of MGMK/TK for GCV is ninefold better (Po0.002) than the catalytic efficiency displayed by wild-type HSVTK towards GCV. These data provide, at least in part, a kinetic explanation for the improved sensitivity of mgmk/TK-transfected tumor cells to GCV. Another possibility is that the fusion protein localizes in transfected cells in a way that provides a more efficient cell killing effect.
Many nucleoside analogs require activation by several different enzymes before they can exert their cytotoxic effects. Evidence suggests that not all enzymes involved in a pathway act efficiently and thus can lead to an accumulation of potentially toxic intermediate products, for example, AZT-MP. Several groups now recognize this as a rate-limiting step for antiviral, antineoplastic and Figure 2 GCV sensitivity assays. In all, 10 mg of each DNA (pREP8D7: dual-GFP (vector alone), pREP8D7:mgmk-GFP, pREP8D7:TK-GFP and pREP8D7:mgmk/TK-GFP) was used to transfect 1 Â 10 6 rat C6 glioma cells by electroporation. Cells were grown in Dulbecco's modified Eagle's medium plus supplements (5% fetal bovine serum, 1 mM sodium pyruvate, 10 mM HEPES, 100 mM nonessential amino acids, 100 U/ml penicillin G, 10 mg/ml streptomycin sulfate, 292 mg/ml Lglutamine, 100 mM sodium citrate and 0.0014% NaCl). After 2 days of incubation, the medium was replaced with DMEM minus histidine plus supplements containing 0.25 mM histidinol. After 2 weeks, histidinol-resistant clones (100-500) were collected and pooled. Approximately 200 000 pooled transfectants were bulk sorted using a MoFlo cell sorter (Cytomation, Fort Collins, CO, USA) based on photoactivation and emission of green fluorescent protein (GFP). Data was analyzed using Cyclops software (Cytomation). To determine the cytotoxicity of GCV, pools of transfectants were transferred to 96-well microtiter plates at an initial density of 600 cells per well in DMEM plus supplements. 11 After cell adherence overnight, GCV (0-100 mM) was added in sets of eight wells for each concentration tested. The plates were incubated for 6 days at which time the redox indicator dye Alamar Blue was added. Cell survival was determined several hours later as according to the manufacturer's instructions and is plotted with standard deviation bar. Legend: pREP8D7:dual-GFP (vector alone; &), pREP8D7:mgmk-GFP ('), pREP8D7:TK-GFP (K) and pREP8D7: mgmk/TK-GFP (m). Overexpression of TK, Mgmk and mgmk/TK from pET vector constructs was as previously reported. 11, 19 Mgmk was expressed from pETHT which fuses a histidine tag to MGMK and the enzyme purified using nickel affinity chromatography. 19 Purification of TK and MGMK/TK was performed by affinity chromatography using CH-Sepharose 4B-coupled p-aminophenylthymidine 3'-phosphate resin as previously described. 11 Phosphorylation of radiolabeled substrates (thymidine and GCV) was detected by a filter-binding assay 11 and GMK assays (GMP) were carried out as described in Brady et al. 19 Radioisotopes for kinetic assays: [methyl-3 H]thymidine (specific activity, 85 Ci/mmol) was purchased from Amersham and [8- 3 H]ganciclovir (specific activity, 17.6 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA, USA). Data were plotted as the double reciprocal of velocity (min/mmole Â 10 4 ) versus substrate concentration (mM À1 ) and the intercepts values used to determine K m and V max . These values were used to calculate the k cat from the double reciprocal plot data as per active site (one active site per monomer). Kinetic values were compared using Student's unpaired t-test, using KaleidaGraph 4.01 software: a or b indicates a P-value o0.015 compared to MGMK or TK, respectively. ND, not determined.
Guanylate kinase/thymidine kinase fusion protein CL Willmon et al suicide gene therapeutic applications. [12] [13] [14] We report here the first attempt to overcome the bottleneck in the widely used HSVTK-driven GCV activation pathway using a kinetically favorable fusion protein. By providing effective cell killing at low GCV concentrations, this novel fusion protein could benefit many patients by improving tumor ablation perhaps through an expanded bystander effect and by reducing the side effects associated with the high doses of GCV currently administered.
